4//SEC Filing
Engle James R 4
Accession 0001225208-10-023973
CIK 0001405197other
Filed
Nov 1, 8:00 PM ET
Accepted
Nov 2, 4:15 PM ET
Size
9.5 KB
Accession
0001225208-10-023973
Insider Transaction Report
Form 4
Engle James R
Sr. VP, Information Technology
Transactions
- Sale
Common Stock
2010-11-01$24.37/sh−12,656$308,446→ 2,631 total - Exercise/Conversion
Common Stock
2010-11-01$1.39/sh+12,656$17,592→ 15,287 total - Exercise/Conversion
Options (right to buy)
2010-11-01$1.39/sh−12,656$17,592→ 55,872 totalExercise: $1.39From: 2006-04-01Exp: 2015-11-10→ Common Stock (12,656 underlying)
Footnotes (4)
- [F1]The transaction reported was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 24, 2010.
- [F2]The number of shares reported includes restricted share units representing the right to receive 2,631 shares of the Issuers common stock that will vest in three equal annual installments beginning April 1, 2011, as detailed in a restricted share unit award agreement by and between the Issuer and the Reporting Person, dated as of September 30, 2009.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.29 to $24.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F4]The option is fully vested and immediately exercisable.
Documents
Issuer
Talecris Biotherapeutics Holdings Corp.
CIK 0001405197
Entity typeother
Related Parties
1- filerCIK 0001472090
Filing Metadata
- Form type
- 4
- Filed
- Nov 1, 8:00 PM ET
- Accepted
- Nov 2, 4:15 PM ET
- Size
- 9.5 KB